ArticlePLoS neglected tropical diseases2025
Decade-long protection of the mumps vaccine: Insights from a large-scale serological study.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSerological surveys of mumps are important for estimating susceptibility in the population and for evaluating the effectiveness of current vaccination strategies.
methodsA cross-sectional serological survey using an enzyme-linked immunosorbent assay was conducted on 5,147 participants in Guangdong, China, to evaluate the immunological effects of 2 doses of measles-mumps-rubella vaccine. In accordance with the instructions of the ELISA kit, the final readings represent the anti-mumps antibody titers, which are expressed in "NovaTec units".
resultsOf the 5,147 participants, 3,888 were positive for mumps IgG antibodies, with a seroprevalence of 75.54% (95% CI: 74.34%-76.71%). For each age group, the mumps IgG seroprevalence rates were 74.40%, 89.02%, 85.58%, 68.60%, 69.28%, 78.42%, and 80.63% for those <8 months, 8 months-2 years, 3-5 years, 6-17 years, 18-39 years, 40-59 years, and>=60 years, respectively. In terms of the percentage decreases in anti-mumps antibody titers, in the population receiving the 1-dose vaccine, there was a mean decrease of 2.06% per year. In the population receiving 2 doses of the vaccine, the mean annual decreases were 10.33% and reached protective thresholds of approximately 12.3 years.
conclusionThe high mumps seroprevalence in the unvaccinated population revealed neglected hidden mumps infections. A time-lapse assay of IgG antibodies indicated that the mumps vaccine provided protection for one decade, which highlights that booster vaccinations may be needed in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.